Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin

Yuki Matsumoto, Mario Tsuchiya, Shakespear Norshalena, Chikako Kaneko, Jin Kubo, Teiji Yamamoto, Toshiyuki Takahashi and Kazuo Fujihara

Abstract
A 26-year-old, 17-week pregnant woman developed aquaporin-4-IgG-positive severe longitudinally extensive transverse myelitis during the course of disseminated herpes zoster and became quadriparietic. She was unresponsive to high-dose intravenous methylprednisolone but became able to walk without assistance after intravenous immunoglobulin. One and a half months later, left optic neuritis developed but her vision improved with intravenous immunoglobulin. The only sequela was left T5 girdle sensation, and she delivered a healthy baby. Intravenous immunoglobulin may be a rescue therapy in aquaporin-4-IgG-positive neuromyelitis optica attacks in pregnant women, especially those with severe infections.

Keywords: Neuromyelitis optica, aquaporin-4-IgG, pregnancy, intravenous immunoglobulin, acute treatment, herpes zoster

Date received: 10 August 2017; revised 28 December 2017; accepted: 5 January 2018

Introduction
Aquaporin-4 (AQP4)-antibody-seropositive neuromyelitis optica (NMO) often affects women in their childbearing years. There have been only a few reports of acute-phase treatment in pregnant patients with seropositive NMO. In relapses of seropositive NMO, the first-line therapy is intravenous methylprednisolone (IVMP), and plasma exchange (PLEX) is a rescue therapy in those unresponsive to IVMP. There are also several reports suggesting therapeutic efficacy of intravenous immunoglobulin (IVIg) in acute-phase NMO but there are no reports of pregnant patients with seropositive NMO treated with IVIg as a rescue therapy.

Here we describe a pregnant woman who developed seropositive NMO following disseminated herpes zoster. She was refractory to IVMP but successfully treated with IVIg. We obtained the patient’s written consent and the institutional review board’s approval for publication.

Case report
The patient was a 26-year-old pregnant woman (gravida 3 partus 2). In May 2016, the patient felt burning pain over her neck, both arms and anterior chest. One week later, she had vesicular skin lesions with crusts and erosions suggestive of varicella zoster infection in those areas. After two more weeks, she had left hemiparesis that then progressed to quadriparesis. In her 17th week of pregnancy, the patient was referred to our hospital by a local obstetrician.

On admission, the patient was bedridden and could not even sit up. She had a high fever (38.8°C) and
severe tingling pain below the neck level aggravated by minor stimuli, which was compatible with allodynia. She also had constipation lasting a week. Physical examination revealed oral candidiasis and vesicles accompanied by crusts and erosions over her right C4, bilateral C5–6 and left Th3 areas. Neurological examination showed profound quadriparesis (manual muscle strength of Medical Research Council 3/5 over the arms and 2/5 over the legs), generalized hyperreflexia, severe hypoesthesia in legs and bowel-bladder disturbance. Varicella-zoster virus (VZV) polymerase chain reaction and VZV-immunoglobulin M (IgM) were negative in the cerebrospinal fluid collected at the onset of myelitis. The patient also had hyponatremia (120 mEq/l) that was asymptomatic and resolved on day 8.

Brain and spinal magnetic resonance imaging (MRI) revealed a left hypothalamic T2-hyperintense lesion and a longitudinally extensive transverse lesion extending from the lower medulla down to Th6 (Figure 1). However, she did not have dyspnea, hiccups or nausea/vomiting. The patient was treated with acyclovir (1500 mg/day) and heparin.

We suspected NMO at that point, and administered intravenous methylprednisolone (IVMP) (1 g/day for five days) on the day of admission. However, her symptoms deteriorated and she became completely paraplegic. Then, we treated her with intravenous immunoglobulin (IVIg) (0.4 mg/kg/day) rather than plasma exchange (PLEX) because of risks of suspected sepsis and circulatory instability affecting the fetus.

After IVIg was given on days 6 and 7, she developed a headache, and thus we discontinued the therapy. Although she barely moved her toes on day 7, she became able to raise her right knee on day 10. On day 13, serum AQP4-immunoglobulin G (IgG) was found to be strongly positive (titers > 75 U/ml), thus fulfilling the diagnostic criteria of NMO with

Figure 1. (a) Spinal magnetic resonance imaging on day 2 exhibited a T2-hyperintense lesion extending from the medulla oblongata to the thoracic cord. (b) Axial image at the C1 level revealed an extensive lesion, mainly involving the central gray matter. (c) Axial image at the midbrain level showed a left hypothalamic lesion. (a) and (b): T2-weighted images. (c): Fluid-attenuated inversion recovery image.
AQP4-IgG. The patient could not even brush her teeth on day 6 but was able to eat her meals without assistance on day 13. Then she received additional doses of IVIg from day 15 to day 17 with no side effects. Following this, she became able to raise her knees on day 16, dorsiflex her ankles on day 17 and stand up with assistance on day 21. She was given IVIg again from day 25 to day 29 and was able to walk with a walker on day 33. She needed laxatives and disimpaction for constipation and placement of an indwelling urinary catheter for urinary retention until day 29. But urinary and bowel symptoms improved thereafter and herpes zoster was epithelialized and scarred by day 33.

On day 41, she noticed left orbital pain and blurred vision. Her left visual acuity was 20/200 and upper altitudinal hemianopia was observed, indicating the development of left optic neuritis. Then, IVMP (1 g/day for five days) was given but she was refractory to it (20/400 in one week). She was then treated with the same doses of IVIg again but it had to be discontinued because of vomiting two days later. When she was discharged on day 70, she was able to read the headline of a newspaper with remaining girdle sensation over the left T5 level. A month later, the patient gave birth at 37 weeks' gestation to a baby without any complications via spontaneous vaginal delivery. Her visual acuity gradually returned to normal although she still had the left T5 girdle sensation.

Discussion

Rescue therapy for severe NMO attacks refractory to IVMP in pregnant women with concomitant infections is not well established. There have been two cases of acute exacerbations of NMO in pregnancy that failed to respond to PLEX but were successfully treated with corticosteroid-resistant NMO attacks. In our patient with corticosteroid-resistant NMO attacks, we chose IVIg rather than PLEX on the assumption that IVIg might also be effective for infections (disseminated herpes zoster) as well as NMO. In fact, cases of infectious or parainfectious NMO/longitudinally extensive transverse myelitis (LETM) (mostly associated with herpes zoster) have been reported (Jarius S, et al. J Neurol Sci. 2009) and there are some reports on safety and efficacy of IVIg in immune-mediated diseases with concomitant infections (Simoes J, et al. J Clin Immunol 2013). Possible mechanisms of IVIg efficacy in NMO spectrum disorder (Wingerchuk DM. J Clin Immunol 2013) may include modulations of AQP4-IgG binding and complement activation and B-cell function.

Table 1. (a) Case reports of therapeutic plasma exchange in AQP4-IgG-positive NMO during pregnancy and (b) case reports of intravenous immunoglobulin therapies in acute phase of AQP4-IgG-positive NMO.

| Table 1 (a) | Age (gestation weeks) | Onset or relapse | Clinical symptoms and MRI findings | Acute treatment before PLEX | Times of PLEX | Effects of PLEX | Reference |
|-------------|------------------------|-----------------|-----------------------------------|-----------------------------|--------------|----------------|-----------|
| Case 1      | 25 (17)                | Relapse         | Respiratory failure, cervical and thoracic LETM | Corticosteroids (unknown details) | Four times | Complete recovery | Cornelio 2009 |
| Case 2      | 27 (20)                | Relapse         | Paraplegia, cervical and thoracic LETM | IVMP                        | Five times | Partial recovery | Rubio Tabares 2016 |

| Table 1 (b) | Age, sex | Onset or relapse | Clinical symptoms and MRI findings | Acute treatment before IVIg | Effects of IVIg | Reference |
|-------------|----------|-----------------|-----------------------------------|-----------------------------|----------------|-----------|
| Case 3      | 49, F    | Onset           | Gait disturbance, myelitis from Th4 to Th6 | IVMP                        | 0.4 g/kg per day over five days | Complete recovery | Li 2008 |
| Case 4      | 81, M    | Onset           | Paraplegia, myelitis from Th5 to Th1 | IVMP                        | Unknown | Complete recovery | Nakano 2009 |
| Case 5      | 32, F    | Onset           | Cognitive impairment, periventricular white matter lesions | IVMP                        | 0.4 g/kg per day over five days | Partial recovery | Stübgen 2012 |
| Case 6      | 37, M    | Onset           | Cognitive impairment, periventricular white matter lesions | IVMP                        | 0.4 g/kg per day over five days | Partial recovery | Stübgen 2012 |

(continued)
| Table 1 (a) | Age (gestation weeks) | Onset or relapse | Clinical symptoms and MRI findings | Acute treatment before PLEX | Times of PLEX | Effects of PLEX | Reference |
|------------|-----------------------|------------------|-----------------------------------|-----------------------------|---------------|----------------|-----------|
| Case 7     | 28, F                 | Relapse          | ON                                | IVMP                        | Unknown       | Partial recovery | Romanelli 2014 |
| Case 8     | 66, F                 | Onset            | ON and myelitis                   | Corticoids (unknown details)| Unknown       | Complete recovery| Hervás-García 2014 |
| Case 9     | 43, F                 | Relapse          | Respiratory failure, cervical myelitis | None                        | 2 g/kg per day over five days | Partial recovery | Elsone 2014 |
| Case 10    | 38, F                 | Relapse          | Bilateral ON                      | PLEX, oral PSL             | 2 g/kg per day over five days | No improvement  | Elsone 2014 |
| Case 11    | 49, F                 | Relapse          | Paraplegia, thoracic LETM         | IVMP                        | 2 g/kg per day over five days | No improvement  | Elsone 2014 |
| Case 12    | 40, F                 | Relapse          | Tetraplegia and heart failure, cervical LETM | IVMP followed by oral PSL | 2 g/kg per day over five days | Partial recovery | Elsone 2014 |
| Case 13    | 79, F                 | Relapse          | Tetraplegia, cervical LETM        | IVMP followed by oral PSL | 2 g/kg per day over five days | No improvement  | Elsone 2014 |
| Case 14    | 57, M                 | Relapse          | Tetraplegia, cervical and thoracic LETM | IVMP                        | 2 g/kg per day over five days | Improved to baseline function | Elsone 2014 |
| Case 15    | 38, F                 | Relapse          | Tetraplegia, cervical LETM        | IVMP, PLEX followed by oral PSL | 2 g/kg per day over five days | Improved to baseline function | Elsone 2014 |
| Case 16    | 55, M                 | Relapse          | Bilateral ON                      | Oral PSL                   | 2 g/kg per day over five days | No improvement  | Elsone 2014 |

AQP4: aquaporin 4; F: female; IgG: immunoglobulin G; IVIg: intravenous immunoglobulin; IVMP: intravenous methylprednisolone; LETM: longitudinally extensive transverse myelitis; ON: optic neuritis; M: male; MRI: magnetic resonance imaging; NMO: neuromyelitis optica; PLEX: plasma exchange; PSL: prednisolone.
Moreover, IVIg is unlikely to cause circulatory instability adversely affecting the fetus, in contrast to PLEX. Despite short-term IVIg administrations because of adverse effects, the patient experienced significant neurological improvement of LETM while the improvement of optic neuritis was slower. IVIg has also been reported to be safe in neuroimmunological disorders such as myasthenia gravis and pregnancy.12

In NMO, 14 cases (15 attacks) treated with IVIg as a rescue therapy have been reported in the literature and IVIg was efficacious in 10 attacks (Table 1(b)).2–7 The main reason why IVIg was administered in those cases was unresponsiveness to IVMP or PLEX. In some patients unresponsive to IVIg, the median time from relapse to IVIg was longer than the intervals in those who responded to IVIg (3.5 months vs a week), suggesting early institution of IVIg is associated with better outcomes.7 Owing to clinical deterioration during IVMP, IVIg was started without delay in our patient, which probably contributed to a favorable therapeutic response although a delayed effect of IVMP cannot be completely ruled out. Given that many women with seropositive NMO are of childbearing age, IVIg may be useful as rescue therapy in AQP4-IgG-positive NMO attacks refractory to IVMP in pregnant patients, especially when complicated with infectious diseases.

Conflict of Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Y. Matsumoto, M. Tsuchiya, S. Norshalena, C. Kaneko, J. Kubo and T. Yamamoto have nothing to declare. T. Takahashi has received speaker honoraria from Biogen Idec and Cosmic Corporation and research support from Cosmic Corporation. K. Fujihara serves on the advisory boards for Bayer Schering Pharma, Biogen Idec, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Alexion Pharmaceuticals, and Medimmune; has received travel funding and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, Asahi Kasei Medical Co, Daichi Sankyo, and Nihon Pharmaceutical; is on the editorial board for Clinical and Experimental Neuroimmunology; and has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, Genzyme Japan, the Ministry of Education, Science and Technology of Japan, and the Ministry of Health, Welfare and Labor of Japan.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Yuki Matsumoto http://orcid.org/0000-0003-0163-8105

References
1. Rubio Tabares J and Amaya Gonzalez PF. Plasma exchange therapy for a severe relapse of Devic’s disease in a pregnant woman: A case report and concise review. Clin Neurol Neurosurg 2016; 148: 88–90.
2. Stübgen JP. Subacute encephalopathy associated with aquaporin-4 autoantibodies: A report of 2 adult cases. Clin Neurol Neurosurg 2012; 114: 1110–1113.
3. Romanelli RG, Fassio F, Cappelli F, et al. Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. Clin Res Hepatol Gastroenterol 2014; 38: 33–35.
4. Ii Y, Sasaki R, Naito Y, et al. Reversible stenosis of large cerebral arteries in a patient with combined Sjögren’s syndrome and neuromyelitis optica spectrum disorder. Rheumatol Int 2008; 28: 1277–1280.
5. Hervás-García JV, Grau-López L, Doménech-Puigcerver S, et al. Encephalopathy and neuromyelitis optica: The importance of recognising atypical symptoms [article in Spanish]. Rev Neurol 2014; 56: 20–24.
6. Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients. Mult Scler 2014; 20: 501–504.
7. Nakano Y, Miyamoto K, Inatsumi Y, et al. Senile-onset recurrent myelitis with anti-aquaporin-4 antibody [article in Japanese]. Brain Nerve 2009; 61: 601–604.
8. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–815.
9. Cornelio DB, Braga RP, Rosa MW, et al. Devic’s neuromyelitis optica and pregnancy: Distinction from multiple sclerosis is essential. Arch Gynecol Obstet 2009; 280: 475–477.
10. Simoes J, Sciascia S, Camara I, et al. Use of intravenous immunoglobulin in patients with active vasculitis associated with concomitant infection. *J Clin Rheumatol* 2015; 21: 35–37.

11. Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. *J Clin Immunol* 2013; 33: S33–S37.

12. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology* 2016; 87: 419–425.